L & R Logo
The National Institute for Health and Care Excellence recommends patented monofilament fibre technology, Debrisoft, for the treatment of acute and chronic wounds in the NHS
A different approach to chronic wound care
There are 2.2 million long-standing wounds in the UK, costing the NHS £5.3bn annually. The cost of wound care in the UK is rising and is putting considerable strain on to the NHS’s finite resources. Wound care in the UK is predominately a nurse-led discipline and the number of skilled staff in the NHS is set to trend downwards, yet the demands of patients with wounds still need to be met. Therefore, it is crucial that different approaches to wound care are made to heal wounds quicker, reduce suffering and make best utilisation of NHS resources.
There are many different ways of cleaning and removing dead tissue and cells from a wound. Some methods require high levels of training and skill, while
others take multiple visits from the nurse to be effective. A brand new form of treatment was brought to the UK in 2011 – Debrisoft®, manufactured by Lohmann & Rauscher.
The National Institute for Health and Care Excellence (NICE) first recommended the use of Debrisoft® Pad (10x10cm) in its medical technologies guidance in 2014, and the guidance has been under review since the beginning of 2018. Following a comprehensive review, NICE’s medical technology guidance has now recommended Debrisoft Pad (10x10cm), Debrisoft® Lolly and Debrisoft Pad (13x20cm) as part of the management of acute or chronic wounds in the community.
“In our wound toolkit, Debrisoft is an essential item for chronic wound care”
Alison Schofield, tissue viability clinical nurse specialist
NICE is a well-respected national body that makes evidence-based recommendations developed by independent committees. NICE’s role is to improve outcomes for people using the NHS and other public health and social care services. Medical technologies guidance helps to ensure that the NHS is able to adopt clinically and cost-effective technologies quickly and effectively.
The NICE committee behind the guidance concluded that using the Debrisoft family would improve speed of debridement, reduce costs and result in a reduction in nursing visits compared to other forms of debridement. The evidence also showed that the treatment is well-tolerated by patients.
Debrisoft Pad and Debrisoft Lolly consist of soft, polyester monofilament fibres. These fibres are cut at a different angle, length and thickness to ensure a positive effect and flexibility. When used in circular motions across the wound area, the fibres clean and remove debris, bacteria and other barriers to healing from the wound bed to ensure the wound can heal.
Wound debris and dead skin cells create an ideal breeding ground for bacteria, which can lead to infection. Using Debrisoft and/or Debrisoft Lolly to remove this from your skin or wound can help the healing process. The Debrisoft family can be used by all health professionals and patients, and only take 2-4 minutes to treat the wound or area of skin.
Alison Schofield, tissue viability clinical nurse specialist at North Lincolnshire and Goole NHS Foundation Trust commented on Debrisoft and the recommendation from NICE:
“As a tissue viability specialist nurse supporting clinicians in best practice for wound assessment and management, we encourage the maintenance of the optimum wound bed environment and with that preparation is vital. A simple effective intervention for this is the Debrisoft Pad along with the added benefit of the Debrisoft Lolly. In our wound toolkit, Debrisoft is an essential item for chronic wound care aiding mechanical debridement. Having evidence-based NICE guidance ensures quality care is delivered.”
To read the NICE guidance on the Debrisoft range in full visit www.nice.org.uk/guidance/mtg17
For more information on Debrisoft visit www.debrisoft.co.uk